Table 1 Hydrogel dressings for diabetic wounds in completed or ongoing clinical trials from the National Library of Medicine
Hydrogel dressing | Conditions or diseases | Clinical phases | Status | Clinical trials numbers | Date | Marketed |
|---|---|---|---|---|---|---|
AmeriGel® | Type 1 diabetes; Type 2 diabetes; DFUs | 4 | Terminated (study closed due to recruitment problems) | NCT01350102 | 2012.04–2014.03 | No |
Fitostimoline® hydrogel | Diabetic foot | 4 | Completed | NCT05661474 | 2021.02–2022.12 | Yes |
SANTYL® | DFUs; Diabetic foot wounds | 4 | Completed | NCT02111291 | 2014.04–2015.12 | Yes |
Woulgan Gel | DFU | 4 | Completed | NCT02631512 | 2015.10–2019.04 | Yes |
ALLO-ASC-DFU (hydrogel sheet containing allogenic mesenchymal stem cells) | DFU | 1 | Completed | NCT03183726 | 2016.01–2017.07 | No |
Hydrogel Purilon® | Diabetic foot; Diabetic Neuropathy; Foot ulcer | 2 | Completed | NCT03700580 | 2012.08–2016.10 | No |
IZN-6D4 Gel | DFU | 2 | Completed | NCT01427569 | 2012.03–2015.08 | No |
Lavior Diabetic Wound Gel | DFU | 2 | In progress | NCT05607979 | 2022.12–2023.06 | No |
NanoDOX™ Hydrogel | DFU | 2 | Completed | NCT00764361 | 2009.01–2010.08 | No |
TWB-103 (mixture of TWB-102 cell and TWB-103 hydrogel) | DFU | 1/2 | Unknown | NCT03624023 | 2019.12–2021.07 | No |
Hydrogel with 3% sodium pentaborate pentahydrate | Wound healing | 1 | In progress | NCT02241811 | 2014.09–2023.12 | No |
RMD-G1 (a hydrogel containing erythropoietin) | DFU | 1 | Completed | NCT02361931 | 2016.03–2018.06 | No |
Cadexomer iodine gel | DFU | Not applicable | Terminated (recruitment challenges) | NCT02181621 | 2014.08–2015.10 | No |
Hydrogel/nano silver-based dressing | Diabetes mellitus | Not applicable | Completed | NCT04834245 | 2019.01–2019.12 | No |
Regranex® | DFU | Not applicable | Unknown | NCT00446472 | 2007.04–2010.09 | No |
Solosite gel | DFU | Not applicable | Terminated | NCT02181621 | 2014.08–2015.10 | No |
ConvaTec DuoDERM Hydroactive Gel | DFU | Not applicable | Completed | NCT00971048 | 2009.09–2011.01 | No |